Cipla USA, Inc.: Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 30
Read the official notice at FDA (drug) →
The text below is copied from the official FDA (drug) record. If anything differs, the official notice is correct.
- Company / brand
- Cipla USA, Inc.
- Product
- Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17
- Reason / hazard
- Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
- Classification
- Class III
- Status
- Ongoing
- Distribution / sold at
- U.S.A. Nationwide
- Recall initiated
- 2026-02-18
- Code info
- Lot #: 5GJ0223, Exp 04/30/2027
- Product quantity
- 164 cartons
- Voluntary mandated
- Voluntary: Firm initiated
- City
- Warren
- State
- NJ
- Country
- United States
- Event id
- 98452
Free daily digest + "My products" watchlist